Substance use and mental health outcomes for comorbid patients in psychiatric day treatment

Substance Abuse: Research and Treatment

Volumn 3, Issue 1, 2009, Pages 71-78

  Magura, Stephen ^a   Rosenblum, Andrew ^b   Betzler, Thomas ^c  

^a WESTERN MICHIGAN UNIVERSITY   (United States)

^b NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Co occurring disorders; Comorbidity; Psychiatric treatment; Substance abuse; Treatment outcomes

Indexed keywords

AMPHETAMINE; CANNABIS; COCAINE; METHAMPHETAMINE; OPIATE DERIVATIVE; SEDATIVE AGENT;

ADULT; ANXIETY DISORDER; ARTICLE; BIPOLAR DISORDER; CLINICAL ASSESSMENT TOOL; COLORADO SYMPTOM INDEX; COMORBIDITY; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISTRESS SYNDROME; DRUG USE; EMPLOYMENT STATUS; ETHNICITY; FEMALE; HEALTH PROGRAM; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; MENTAL HEALTH; MOOD DISORDER; OUTCOME ASSESSMENT; PSYCHIATRIC TREATMENT; PSYCHOSIS; QUALITY OF LIFE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF REPORT; SUBSTANCE ABUSE; SYMPTOM CHECKLIST 10; TREATMENT OUTCOME; URINALYSIS;

EID: 77956465086     PISSN: None     EISSN: 11782218     Source Type: Journal    
DOI: 10.4137/sart.s3462     Document Type: Article

References (44)

1. Substance Abuse and Mental Health Services Administration, Office ofApplied Studies. Results from the 2007 National Survey on Drug Use andHealth: National Findings (NSDUH Series H-34, DHHS Publication No.SMA 08-4343). Rockville, MD, 2008.
2. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence,severity, and comorbidity of 12-month DSM-IV disorders inthe National Comorbidity Survey Replication. Arch Gen Psychiatry.2005;62(6):617-27.
3. Hagnell O, Grasbeck, A. Comorbidity of anxiety and depression in theLunby 25-year prospective study The pattern of subsequent episodes. In:Comorbidity of Mood and Anxiety Disorders. Maser JD, Cloninger CR,eds. Washington, DC: American Psychiatric Press; 1990:139-52.
4. Hirschfeld RMA, Hasin D, Keller MB, Endicott J, Wunder J. Depressionand alcoholism: Comorbidity in a longitudinal study. In: Comorbidity ofMood and Anxiety Disorders. Maser JD, Cloninger CR, eds. Washington,DC: American Psychiatric Press; 1990:293-304.
5. Kessler RC. The national comorbidity survey: preliminary results andfuture directions. International Journal of Methods in Psychiatric Research.1995;5:139-51.
6. Murphy JM Diagnostic comorbidity and symptom co-occurrence: the StirlingCounty Study. In: Comorbidity of Mood and Anxiety Disorders. MaserJD, Cloninger CR, eds. Washington, DC: American Psychiatric Press;1990;153-76.
7. Gonzalez G, Rosenheck R. Outcome and service use among homeless personswith serious mental illness and substance abuse. Psychiatric Services.2002;53(4):437-46.
8. Donat DC, Haverkamp J. Treatment of psychiatric impairment complicatedby co-occurring substance use: impact of rehospitalization. Psych Rehab J.2004;28 (1):78-82.
9. McLellan AT, Luborsky L, Woody GE, O'Brien CP, Druley, K. Predictingresponse to alcohol and drug abuse treatments: Role of psychiatric severity.Arch Gen Psychiatry. 1983;40:620-25.
10. Rounsaville BJ, Kosten TR, Weissman MM, Kleber D. Prognostic significanceof psychopathology in treated opiate addicts. Arch Gen Psychiatry.1986;43:739-45.
11. Walker RD, Donovan DM, Kiivaha, DR, O'Leary MR. Length of stay,neuropsychological performance, and aftercare: Influences on alcohol treatmentoutcome. J Consult Clin Psychol. 1983;51:900-11.
12. Bartels SJ, Teague GB, Drake RE, Clark RE, Bush PW, Noordsy DL. Substanceabuse in schizophrenia: Service utilization and costs. J Nerv MentDis. 1993;181:227-32.
13. Bergman HC, Harris M. Substance abuse among young adult chronicpatients. Psychosocial Rehabilitation Journal. 1985;9:49-54.
14. Buckley PF, Brown ES. Prevalence and consequences of dual diagnosis.J Clin Psychiatry. 2006;67(7):e01.
15. Compton MT, Weiss PS, West JC, Kaslow NJ. The associations between substanceuse disorders, schizophrenia-spectrum disorders, and Axis IV psychosocialproblems. Soc Psychiatry Psychiatr Epidemiol. 2005;40(12):939-46.
16. Drake RE, Brunette MF Complications of severe mental illness relatedto alcohol and drug use disorders. In: Galanter M. (Ed.) Recent Developmentsin Alcoholism, Vol. 14: The Consequences of Alcohol (p. 285-99).New York: Plenum; 1998.
17. Mueser KT, Bellack AS, Blanchard JJ. Comorbidity of schizophreniaand substance abuse: Implications for treatment. J Consult Clin Psychol.1992;60:845-56.
18. Osher FC, Kofoed LL. Treatment of patients with psychiatric and psychoactivesubstance use disorders. Hospital and Community Psychiatry.1989;40(10):1025-30.
19. Osher FC, Drake RE, Noordsy DL. Correlates and outcomes of alcohol usedisorder among rural outpatients with schizophrenia. J Clin Psychiatry.1994;55:109-13.
20. Westermeyer J, Walzer V. Sociopathology and drug abuse in a young psychiatricpopulation. Diseases of the Nervous System. 1985;36:673-77.
21. Rosenberg SD, Drake RE, Brunette MF, Wolford GL, Marsh BJ. Hepatitis Cvirus and HIV co-infection in people with severe mental illness and substanceuse disorders. AIDS. 2005;19(3):S26-33.
22. Gotham JJ, Brown JL, Comaty JE, McGovern MP. Dual Diagnosis Capabilityin Mental Health Treatment (DDCMHT) Version 3.2. http://dms.dartmouth.edu/prc/dual/pdf/ddcmht_index.pdf. Accessed Sept 9, 2009.
23. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the AddictionSeverity Index. J Subst Abuse Treat. 1992;9(3):199-213.
24. Shern DL, Wilson NZ, Coen AS, et al. Client outcomes II: longitudinal clientdata from the Colorado treatment outcome study. The Milbank Quarterly.1994;72(1):123-48.
25. Boothroyd RA, Chen HJ. The psychometric properties of the ColoradoSymptom Index. Adm Policy Ment Health. 2008;35(5):370-8.
26. Rosen C, Dreschler K, Moos R, Finney J, Murphy R, Gusman F. Six and tenItem indices of psychological distress based on the Symptom Checklist-90.Assessment. 2000;7:103-11.
27. Watson D, Clark LA, Tellegen A. Development and validation of brief measuresofpositive and negative affect: The PANAS scales. Journal of Personalityand Social Psychology. 1988;54(6):1063-70.
28. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoymentand Satisfaction Questionnaire: a new measure. PsychopharmacologicalBulletin. 1993;29(2):321-6.
29. Bishop SL, Walling DP, Dott SG, Folkes CC, Bucy J. Refining quality oflife: Validating a multidimensional factor measure in the severe mentally ill.Quality of Life Research. 1999;8(1-2):151-60.
30. Magura S, Spybrook J, Rosenblum A, et al. Undiagnosed drug use amongadmissions to psychiatric day treatment and prediction of early exit.(In submission).
31. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, et al, The Mini InternationalNeuropsychiatric Interview (M.I.N.I.): The Development and Validationof a Structured Diagnostic Psychiatric Interview. J Clin Psychiatry.1998;59(Suppl 20):22-33.
32. Center for Substance Abuse Treatment. Substance abuse treatment for personswith co-occurring disorders. Treatment Improvement Protocol (TIP)Series 42. DHHS Publication no. (SMA) 05-3992. Rockville MD: SubstanceAbuse and Mental Health Services Administration, 2005.
33. Flynn PM, Brown BS. Co-occuring disorders in substance abusetreatment: Issues and prospects. J Substance Abuse Treatment. 2008;34(1):36-47.
34. Dixon L, McNary S, Lehman AF. Remission of substance use disorderamong psychiatric inpatients with mental illness. Am J Psychiatry. 1998;155(2):239-43.
35. Caspari D. Cannabis and schizophrenia: results of a follow-up study. EurArch Psychiatry Clin Neurosci. 1999;249(1):45-9.
36. Hunt GE, Bergen J, Bashir M. Medication compliance and comorbid substanceabuse in schizophrenia: impact on community survival 4 years aftera relapse. Schizophr Res. 2002;54(3):253-64.
37. Sacks S, Banks S, McKendrick K, Sacks JY. Modified therapeutic communityfor co-occurring disorders: a summary of four studies. J Subst AbuseTreat. 2008;34(1):112-22.
38. Drake RE, O'Neal EL, Wallach MA. A systematic review of psychosocialresearch on psychosocial interventions for people with co-occurringsevere mental and substance use disorders. J Subst Abuse Treat. 2008;34(1):123-38.
39. Harris KM, Edlund MJ. Use of mental health care and substance abusetreatment among adults with co-occurring disorders. Psychiatr Serv. 2005;56(8):954-9.
40. Margolese HC, Negrete JC, Tempier R, Gill K. A 12-month prospectivefollow-up study of patients with schizophrenia-spectrum disorders andsubstance abuse: changes in psychiatric symptoms and substance use.Schizophr Res. 2006;83(1):65-75.
41. Case N. The dual-diagnosis patient in a psychiatric day treatment program:a treatment failure. J Substance Abuse Treatment. 1991;8(1-2):69-73.
42. Chouljian TL, Shumway M, Balancio E, Dwyer EV, Surber R, Jacobs M.Substance use among schizophrenic outpatients: prevalence, course, andrelation to functional status. Ann Clin Psychiatry. 1995;7(1):19-24.
43. Howland RH, Rush AJ, Wisniewski SR, et al. Concurrent anxiety andsubstance use disorders among outpatients with majordepression: clinicalfeatures and effect on treatment outcome. Drug Alcohol Depend. 2009;99(1-3):248-60.
44. Magura S, Kang SY. Validity of self-reported drug use in high risk populations:a meta-analytical review. Subst Use Misuse. 1996;31(9):1131-53.